Sansimeon, Inc.

Sansimeon Inc., a for-profit biomedical research company headquartered in Wilmington, Delaware, develops high-throughput single-cell sequencing platforms and instruments as a federal grant recipient, working exclusively with the National Institutes of Health on Phase I and Phase II Small Business Innovation Research (SBIR) awards under the Biomedical Research and Research Training program.

The vendor's federal footprint consists entirely of prime grant awards to NIH institutes. The National Institute of General Medical Sciences has funded three awards totaling development of integrated single-cell sequencing platforms capable of processing up to 100 million cells per run for translational and clinical research applications, including immunotherapy development, precision diagnostics, and minimal residual disease detection. A June 15, 2026 project grant of $382,798 (completion May 31, 2027) focuses on developing a fully integrated platform unifying sample preparation, cell enrichment, multiplexed tagging, and cite-seq labeling into a streamlined workflow with an automated benchtop instrument and injection-molded microfluidic cartridge as Phase II deliverables. An August 1, 2023 award (completion July 31, 2027) supports development of a high-throughput platform for scalable single-cell sequencing with automated workflows for direct analysis of peripheral whole blood and dissociated tissue, including computational tools optimization for scaled single-cell datasets. A second August 1, 2023 award (completion July 31, 2024) addresses throughput constraints by leveraging deterministic cell-bead pairing in microchannels without multi-step labeling workflows. The National Human Genome Research Institute issued one award on February 23, 2024 (completion February 22, 2026) targeting development of next-generation cell therapies through high-throughput single-cell sequencing for TCR immune profiling and pooled CRISPR screening, with throughput exceeding 100 million cells. Two awards face ultimate completion within the next twenty-four months. Across all four grants, Sansimeon has obligated approximately $2 million in combined federal funding.